Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.77 |
| ▸ | F2 | P00734 | 4/20 | 0.77 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.77 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.77 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721115 | 0.87 | F10 (1.00) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8170828 | 0.86 | F10 (0.74) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL27518385 | 0.85 | F10 (0.77) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5383621 | 0.82 | F10 (0.64) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7455654 | 0.76 | F10 (0.62) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7133162 | 0.76 | F10 (0.64) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7453349 | 0.75 | F10 (0.78) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7684163 | 0.75 | F10 (0.78) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8169948 | 0.73 | F10 (0.67) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7352218 | 0.73 | F10 (0.53) | F10F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235575-B2 | Guanidine mimics as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-06-26 | — | — | US | disclosed |
| US-6965036-B2 | Intermediates for guanidine mimics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-11-15 | — | — | US | disclosed |
| US-6958356-B2 | Guanidine mimics factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| EP-0991638-B1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6906070-B2 | Anticoagulants | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040063772-A1 | Novel intermediates for guanidine mimics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-01 | — | — | US | disclosed |
| US-20030069258-A1 | Novel guanidine mimics factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-10 | — | — | US | disclosed |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069258-A1 | Novel guanidine mimics factor Xa inhibitors | TFPI, F11, F12 | F10 8/4885F2 11/4885PRSS1 238/4885 |
| US-20040063772-A1 | Novel intermediates for guanidine mimics as factor Xa inhibitors | TFPI, SERPINC1, F11 | F10 13/4885F2 19/4885PRSS1 295/4885 |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | F11, SERPINC1, TFPI | F10 11/4885F2 18/4885PRSS1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.